Our observational and MR analyses provide strong evidence that men with higher circulating IGF‐I have an elevated risk of prostate cancer; furthermore, our observational analyses suggest a higher risk of prostate cancer mortality in these men, suggesting that IGF‐I is associated with risk for more severe forms of prostate cancer and/or may increase the risk of prostate cancer progression. This evidence concerns the gene IGF1 and prostate carcinoma.